Genentech Resumes Xolair Phase IIIb Trial After Clinical Hold Is Lifted

Genentech has resumed development of Xolair following the lifting of a clinical hold, VP-Medical Affairs Stephen Dilly, MD, said at the Robertson Stephens Medical Conference in New York Nov. 29. "We addressed the questions that FDA posed...and now the clinical hold has been lifted and we're in a position to implement our Phase IIIb program as planned," he reported.